Press Releases

DAY HI:
DAY LOW:
VOLUME:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Date Title Format
Aug 18, 2003
Spectrum Pharmaceuticals Reports Second Quarter Financial Results and Highlights Year-to-Date Progress Monday August 18, 9:00 am ET IRVINE, CA--(MARKET WIRE)--Aug 18, 2003 -- Spectrum Pharmaceuticals, Inc. (NasdaqSC:SPPI) today reported a net loss for the second quarter ended June 30, 2003 of $1.6
Aug 14, 2003
Spectrum Pharmaceuticals Completes $3 Million Financing Led by Baystar Capital Thursday August 14, 2:45 pm ET IRVINE, CA--(MARKET WIRE)--Aug 14, 2003 -- Spectrum Pharmaceuticals, Inc. (NasdaqSC:SPPI) today announced that it has raised approximately $3.0 million through the sale of newly issued
Aug 13, 2003
Spectrum Pharmaceuticals to Host Conference Call to Discuss Second Quarter Financial and Operating Results Wednesday August 13, 9:56 am ET IRVINE, CA--(MARKET WIRE)--Aug 13, 2003 -- Spectrum Pharmaceuticals, Inc. (NasdaqSC: SPPI) will hold a conference call on Monday, August 18th at 10:30 a.m.
Aug 11, 2003
Spectrum Pharmaceuticals' Patent Application on Its Anti-Psychotic Drug Platform Is Published Monday August 11, 10:00 am ET IRVINE, CA--(MARKET WIRE)--Aug 11, 2003 -- Spectrum Pharmaceuticals, Inc. (NasdaqSC:SPPI) announced that the U.S. Patent Office has published U.S. Patent Application No.
Jun 11, 2003
Spectrum Reports Positive Phase 1 Data; Will Initiate Phase 2 Study of Eoquin(TM) in Superficial Bladder Cancer Wednesday June 11, 10:00 am ET IRVINE, Calif., June 11 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today reported a complete response in each of the first five
Jun 09, 2003
Spectrum Pharmaceuticals to Host Conference Call to Discuss Recent Developments in Its Oncology Programs Monday June 9, 9:50 am ET IRVINE, Calif., June 9 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) will hold a conference call on Thursday, June 12th at 10:30 a.m.
Jun 03, 2003
Spectrum Pharmaceuticals Reports Positive Clinical Data Presented on Satraplatin in the Treatment of Hormone-Refractory Prostate Cancer at ASCO Satraplatin Achieves Statistically Significant Doubling of Progression-Free Survival Tuesday June 3, 9:07 am ET IRVINE, Calif., June 3
Jun 02, 2003
Spectrum Pharmaceuticals Announces Nasdaq Decision to Continue Company's SmallCap Market listing Listing Qualifications Panel Rules That the Company has Regained Compliance With Listing Requirements Monday June 2, 10:24 am ET IRVINE, Calif., June 2 /PRNewswire-FirstCall/ -- Spectrum
May 19, 2003
Spectrum Pharmaceuticals Nominates Former Pfizer Senior Vice President to Board of Directors Dr. Dilip Mehta Supervised Clinical Trials and New Drug Applications for Blockbuster Drugs Such as Zoloft and Viagra and is Currently an FDA Advisory Committee Member Monday May 19, 5:30 am ET IRVINE,
May 15, 2003
Spectrum Pharmaceuticals Appoints Julius Vida, Ph.D. to Its Board of Directors Dr. Dilip Mehta Supervised Clinical Trials and New Drug Applications for Blockbuster Drugs Such as Zoloft and Viagra and is Currently an FDA Advisory Committee Member Monday May 19, 5:30 am ET IRVINE, Calif., May 19
May 14, 2003
Spectrum Pharmaceuticals Receives Additional $1.56 Million in Financing Total of $6 Million Raised During the First Half of May 2003 Wednesday May 14, 5:54 pm ET IRVINE, Calif., May 14 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that it has raised an
May 13, 2003
Spectrum Pharmaceuticals' Auditor Removes 'Going Concern' Cautionary Paragraph Based on Completion of Recent Financing Tuesday May 13, 8:35 am ET IRVINE, Calif., May 13 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today reported that based on the Company's successful
May 12, 2003
Spectrum Pharmaceuticals Announces Trigger of Milestone Payment on FDA Acceptance of Ciprofloxacin ANDA Filing Monday May 12, 8:31 am ET IRVINE, Calif., May 12 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that the U.S.
May 09, 2003
Spectrum Pharmaceuticals Announces FDA Acceptance of ANDA Filing for Ciprofloxacin Friday May 9, 8:31 am ET IRVINE, Calif., May 9 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that the US Food and Drug Administration (FDA) has accepted for filing its
May 08, 2003
Spectrum Pharmaceuticals Completes $4.44 Million Financing With Institutional Investors Thursday May 8, 8:31 am ET IRVINE, Calif., May 8 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that it has raised $4.44 million through the sale of newly issued shares
Apr 08, 2003
Spectrum Pharmaceuticals Receives Nasdaq Notice Tuesday April 8, 7:08 pm ET IRVINE, Calif., April 8 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that the Company received a Nasdaq staff determination indicating that the Company is not in compliance with
Mar 31, 2003
Spectrum Pharmaceuticals Reports Fourth Quarter and Year End Financials Monday March 31, 8:01 am ET IRVINE, Calif., March 31 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI - News ) today reported a net loss for the fourth quarter ended December 31, 2002 of $3.8 million, or
Feb 07, 2003
Spectrum Pharmaceuticals to Receive $1 Million Investment Investment to Support Accelerated Development of Spectrum's Generic Drug Business Friday February 7, 8:30 am ET IRVINE, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that it has
Jan 15, 2003
Spectrum Pharmaceuticals Announces Filing of First ANDA With the FDA for Approval to Market Generic Drugs in the United States Company Plans Additional Filings During 2003; Looks for Revenue From Generic Business During 2004 Wednesday January 15, 8:33 am ET IRVINE, Calif., Jan.
Dec 19, 2002
Spectrum Pharmaceuticals Completes Equity Offering Thursday December 19, 9:00 am ET IRVINE, Calif., Dec. 19 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) announced today that it had raised $598,500 from three investors through the sale of 285,000 shares of common stock, at
Displaying 781 - 800 of 815